Why the study?
Prior studies assessing sex differences in pulmonary embolism outcomes were limited by small sample sizes, lack of prespecified protocols, or methodological limitations, especially in older adults.
Does female sex affect 30-day mortality and readmission in older adults with pulmonary embolism compared to male sex?
Does female sex affect 30-day mortality and readmission in older adults with pulmonary embolism compared to male sex?
In older adults with pulmonary embolism, females have a significantly higher adjusted risk of 30-day mortality compared to males, despite similar crude mortality rates.
Answers are grounded in this paper and cite their sources.
Higher adjusted 30-day mortality risk in older females with PE warrants caution in risk stratification; leaves open whether sex-specific approaches improve outcomes.
Background: Several studies have assessed sex differences in outcomes of patients with pulmonary embolism (PE). However, they have been limited by small sample sizes, lack of a prespecified protocol, or other methodological problems. Aims: The SERIOUS-PE study was designed for rigorous prespecified analyses in patients aged ≥65 years, a group most likely to suffer from PE and its adverse outcomes. Methods: We used data from the RIETE registry (predominantly representing Europe) and a validated algorithm using ICD-10 codes to identify US Medicare Fee-For-Service beneficiaries with PE. To focus on clinically-relevant differences in clinical characteristics, standardized differences (SRD)>10% were considered. Thirty-day outcomes were assessed in unadjusted and adjusted models. Results: The outcomes analysis included 33,462 patients from RIETE (age 77.6 years, 59.5% female) and 666,128 from Medicare (age 73.5 years, 53.9% female). Females were older than males (SRD: 34% [RIETE] and 30% [Medicare]), and more frequently had varicose veins, immobility, depression, or hormonal therapy (SRD>10%). Males more frequently had atherosclerotic diseases and cancer (SRD>10%). Thrombus burden, PE risk stratification, anticoagulant therapy, and advanced therapies did not have clinically-relevant differences between groups (SRD<5%). 30-day mortality occurred in 6.4% of females and 6.8% of males in RIETE (OR 0.91, 95% CI 0.83-1.00) and 15.2% of females and 16.5% of males in Medicare (OR 0.91, 95% CI 0.90-0.92). After adjusting for age and other covariates, females had a higher risk of mortality than males in RIETE (aOR 1.24, 95% CI 1.11-1.39) and in Medicare (aOR 1.10, 95% CI 1.08-1.13). 30-day readmission occurred in 14.7% of females and 15.1% of males in Medicare (OR 0.97, 95% CI 0.96-0.99, and aOR 1.00, 95% CI 0.98-1.01). Conclusions: This is the most comprehensive assessment of sex differences in presentation, treatment strategies, and outcomes of older adults with PE. Sex differences in crude vs adjusted mortality warrant additional investigation.
No takes yet. Share an insight, caveat, or question.
Bikdeli et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: